18F-FRP-170

18F-FRP-170 (also known as [18F]FRP-170 or 1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole) is a radiolabeled 2-nitroimidazole derivative developed as a positron emission tomography (PET) diagnostic imaging agent for the non-invasive detection of tumor hypoxia. It was originally developed by researchers at Tohoku University based on the radiosensitizer RP-170 from POLA Chemical Industries, and is clinically utilized by institutions such as the Southern Tohoku Drug Discovery and Cyclotron Research Center. As a hydrophilic analog of the widely used hypoxia tracer 18F-FMISO, 18F-FRP-170 offers improved pharmacokinetics, including faster clearance from normoxic tissues and blood, which results in a higher target-to-background ratio and superior image contrast. In hypoxic environments, the nitro group of 18F-FRP-170 undergoes intracellular reduction by nitroreductases, leading to the formation of reactive intermediates that covalently bind to cellular macromolecules, trapping the radiotracer specifically within hypoxic cells. It has been investigated for imaging hypoxia in various cancers, including glioblastoma, lung cancer, and head and neck squamous cell carcinoma.

Other names

1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole[18F]FRP-170[18F]FRP170fluorine-18 FRP-170fluorine18 FRP-170fluorine 18 FRP-170